Company news
Panbela Therapeutics, Inc. (OTC:PBLA) news
Panbela Therapeutics, Inc. news releases on 6ix. Latest, Nov 14, 2024: Panbela Provides Business Update and Reports Q3 2024 Financial Results
Press releases & updates
Panbela Provides Business Update and Reports Q3 2024 Financial Results
November 13, 2024
Panbela to Host Third Quarter 2024 Earnings Conference Call on November 14, 2024
October 30, 2024
First Patient Enrolled in Phase I Program in STK11 Mutant Non-Small Cell Lung Cancer at Moffitt Cancer Center
September 23, 2024
Panbela Provides Business Update and Reports Q2 2024 Financial Results
August 12, 2024
Panbela to Host Second Quarter 2024 Earnings Conference Call on Aug 13, 2024
July 29, 2024
Panbela Therapeutics Announces Third Independent Safety Review of Phase 3 ASPIRE Clinical Trial DSMB Recommended Continuation with No Trial Modification
June 23, 2024
Panbela Announces Oral Presentation at Digestive Disease Week (DDW):
June 9, 2024
Panbela Provides Business Update and Reports Q1 2024 Financial Results
May 14, 2024
Panbela Announces Issuance of New Patent in the US and Canada; Patent is for Claims of a Fixed Dose Combination of Eflornithine and Sulindac
May 5, 2024
Panbela to Host First Quarter 2024 Earnings Conference Call on May 15, 2024
April 30, 2024
Acceptance of Eflornithine (DFMO) Abstract for Oral Presentation at Digestive Disease Week
April 29, 2024
Panbela Therapeutics Announces Interim Data Analysis for ASPIRE Trial Pushed to Q1 2025
April 21, 2024
OTC Markets Group Welcomes New OTCQB Companies – April 22
April 22, 2024
Panbela Announces Poster Presentation at American Association for Cancer Research:
April 17, 2024
Panbela Announces Transfer to OTCQB Market
April 15, 2024
Sun BioPharma, Inc. Announces Pricing of $10.5 Million Public Offering and Uplisting to the Nasdaq Capital Market
August 28, 2020
Sun BioPharma, Inc. Provides Business Update and Reports Q2 2020 Financial Results
August 11, 2020
Sun BioPharma, Inc. Appoints Jennifer K. Simpson, Ph.D., as President and CEO
July 16, 2020
Sun BioPharma, Inc. Receives FDA Fast Track Designation for SBP-101
June 30, 2020
Sun BioPharma, Inc. Provides a Business Update and Reports Q1 2020 Financial Results
May 12, 2020
Sun BioPharma Announces Pause in Enrollment of Clinical Trial of SBP-101 for Patients with Pancreatic Cancer
April 3, 2020
Sun BioPharma Provides Business Update and Reports Operating Results for FY2019
March 24, 2020
Sun BioPharma, Inc. Initiates Search for CEO
January 28, 2020
Sun BioPharma, Inc. Summarizes SBP-101 Phase 1 Clinical Data Presented at ASCO 2020 Annual Gastrointestinal Cancers Symposium
January 24, 2020
Sun BioPharma, Inc. Announces Data Presentation at the ASCO 2020 Annual Gastrointestinal Cancers Symposium
December 23, 2019
Sun BioPharma, Inc. Provides a Business Update and Reports Q3 2019 Financial Results
November 13, 2019
Sun BioPharma, Inc. Provides a Business Update and Files Report for Q2 2019
August 13, 2019
Sun BioPharma, Inc. Provides an Update on Ongoing Front-line Pancreatic Cancer Clinical Trial
July 22, 2019
Sun BioPharma, Inc. Provides a Business Update and Files Report for Q1 2019
May 14, 2019
Sun BioPharma Provides Business Update and Files Annual Report for 2018
March 22, 2019
Sun BioPharma, Inc. Provides a Business Update and Files Report for Q3 2018
November 5, 2018
Sun BioPharma, Inc. to Present Results of New Pancreatitis Study at American Pancreatic Association Meeting in Miami Beach, FL
November 1, 2018
Sun BioPharma, Inc. Announces Leadership Changes
October 31, 2018
Sun BioPharma, Inc. Provides a Business Update and Files Report for Q2 2018
August 13, 2018
Sun Biopharma, Inc. Presents Poster at Pancreasfest in Pittsburgh, Pa.
July 27, 2018
Sun BioPharma, Inc. Doses First Patients in Second Clinical Study of SBP-101 for Pancreatic Ductal Adenocarcinoma
June 13, 2018
Sun BioPharma Provides Business Update and Files Report for Q1 2018
May 14, 2018
Sun BioPharma, Inc. Announces Appointment of Susan Horvath as Vice President of Finance and Chief Financial Officer
April 16, 2018
Sun BioPharma Provides Business Update and Files Annual Report for 2017
March 21, 2018
Sun Biopharma, Inc. Files United States Patent Protecting the Manufacturing Process for Its Lead Drug Candidate, SBP-101
February 27, 2018
Sun Biopharma, Inc. Announces Initiation of First-Line Combination Study of Sbp-101 With Gemcitabine and Nab-Paclitaxel in Patients With Pancreatic Cancer
January 29, 2018
Sun BioPharma Announces Execution of Reverse Stock Split
November 6, 2017
Sun BioPharma Achieves Significant Milestone with Successful Completion of Patient Enrollment in Phase 1a Dose Escalation Safety Study of SBP-101 for Patients with Pancreatic Cancer
October 4, 2017
Sun BioPharma Files Form 10-Q for Second Quarter 2017 and Provides Clinical Update
August 10, 2017
Sun BioPharma, Inc. to Present at the 2017 Marcum MicroCap Conference in New York on June 15, 2017
June 7, 2017
Sun BioPharma, Inc. Announces Completion of the Fifth Patient Cohort in the Dose Escalation Phase 1a Study of SBP-101 for Pancreatic Cancer
June 7, 2017
Sun BioPharma Reports First Quarter 2017 Results
May 11, 2017
Sun BioPharma Provides Phase 1 Trial Update; Patients Experience Early Signs of Efficacy
March 30, 2017
The NIH Awards Sun BioPharma, Inc. Grant to Study SBP-101 for the Treatment of Pancreatitis
February 1, 2017
Sun BioPharma to Initiate Fifth Patient Cohort in its Dose Escalation Phase 1 Study of SBP-101 for Pancreatic Cancer
December 7, 2016